How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions
Monaldi Archives for Chest Disease · 2024
DOI: 10.4081/monaldi.2024.3084 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Monaldi Archives for Chest Disease, 2024. Verfasst von Karin Del Vecchio und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Disopyramide, Echocardiography. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations. Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50-60% of symptomatic children developing a gradient under exertion. Treatment options are limited, and there is a relative lack of data on the pediatric population. Disopyramide is a sodium channel blocker with negative inotropic properties. This therapy effectively reduces LVOTO in adults with HCM and delays surgical interventions, but it is not licensed for use in children. We aimed to review and analyze the influence of disopyramide over the pathophysiological, clinical, electrocardiographic, and echocardiographic characteristics of patients with HCM in infancy, childhood, adolescence, and adult age. While disopyramide remains a cornerstone in the management of pediatric HCM, the advent of mavacamten and aficamten heralds a new era of potential advancements. These emerging therapies could significantly improve the quality of life and prognosis for young patients with HCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Unit, Department for Women's and Children's Health, University Hospital of Padova.
- Pediatric Cardiology Unit, Department of Women's and Children's Health, University of Padova.
ORCID-Profile: Karin Del Vecchio, Caterina Rizzardi, Alice Pozza, Francesco Prati, Luisa Ye, Alessia Fattoretto, Giovanni Di Salvo
Zitieren
APA
Del Vecchio, K., Rizzardi, C., Pozza, A., Prati, F., Ye, L., Fattoretto, A., Reffo, E., & Di Salvo, G. (2024). How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2024.3084
Vancouver
Del Vecchio K, Rizzardi C, Pozza A, Prati F, Ye L, Fattoretto A, et al. How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions. Monaldi Archives for Chest Disease. 2024. doi:10.4081/monaldi.2024.3084
BibTeX
@article{DelVecchio2024,
author = {Del Vecchio, Karin and Rizzardi, Caterina and Pozza, Alice and Prati, Francesco and Ye, Luisa and Fattoretto, Alessia and Reffo, Elena and Di Salvo, Giovanni},
title = {How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions},
journal = {Monaldi Archives for Chest Disease},
year = {2024},
doi = {10.4081/monaldi.2024.3084}
}
EUVIMED